13 completed, 4 terminated, 2 withdrawn, 1 unknown. 20 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 13, Terminated 4, Withdrawn 2, Unknown 1 |
| Phase 1 | 4 | Completed 3, Terminated 1 |
Follow Stage III Melanoma: new trials by email Literature Review of Stage III Melanoma trials Research Report on Stage III Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sargramostim (GM-CSF) + PD-1 Sargramostim (GM-CSF), Pembrolizumab (anti-PD-1) - Unresectable Melanoma, Metastatic Melanoma | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2021-04-16 | 2023-05-22 | |
| Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab - Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV | Phase 2 | Completed | Emory University | 15 | 2019-06-05 | 2026-10-02 |
| TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma Trametinib, Dabrafenib - Stage IV Melanoma, Stage III Melanoma | Phase 2 | Completed | Universitair Ziekenhuis Brussel | 45 | 2019-01-28 | 2023-09-26 |
| Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma Pembrolizumab with All-Trans Retinoic Acid - Stage IV Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Completed | University of Colorado, Denver | 26 | 2017-10-31 | 2024-10-01 |
| Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma Pembrolizumab - Unresectable Malignant Neoplasm, Melanoma | Phase 2 | Completed | St. Louis University | 10 | 2015-01-01 | 2019-06-20 |
| Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma Indoximod, Ipilimumab, Nivolumab - Metastatic Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 131 | 2014-07-01 | 2026-05-29 |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations BRAF inhibitor dabrafenib and MEK inhibitor trametinib - Stage III Melanoma, Stage IV Melanoma | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 17 | 2013-04-04 | 2020-11-23 |
| Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma Ofatumumab, Ofatumumab plus Dacarbazine - Stage III Melanoma, Stage IV Melanoma | Phase 2 | Completed | Medical University of Vienna | 10 | 2011-06-01 | 2015-10-06 |
| Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma MKC1106-MT - Stage III Melanoma, Stage IV Melanoma | Phase 2 | Terminated | Mannkind Corporation | 5 | 2010-10-01 | 2012-05-15 |
| Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma Pazopanib and Paclitaxel - Stage III Melanoma, Stage IV Melanoma | Phase 2 | Completed | University of California, Irvine | 60 | 2010-08-01 | 2019-08-07 |
| Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. Nilotinib - Malignant Skin Melanoma T0, Stage III Melanoma | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 25 | 2010-07-01 | 2011-02-08 |
| Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox - Recurrent Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2009-07-01 | 2022-11-15 |
| VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery ziv-aflibercept, pharmacological study - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2007-06-01 | 2018-05-24 |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma sorafenib tosylate, temsirolimus - Melanoma, Recurrent Melanoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2006-04-01 | 2015-04-15 | |
| Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery sorafenib tosylate, laboratory biomarker analysis - Stage III Melanoma, Stage IV Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 74 | 2005-06-01 | 2013-01-15 |
| Tanespimycin in Treating Patients With Stage III-IV Melanoma tanespimycin, laboratory biomarker analysis - Recurrent Melanoma, Stage III Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 50 | 2004-06-01 | 2013-04-10 |
| Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma cilengitide, pharmacological study, laboratory biomarker analysis - Stage III Melanoma, Stage IV Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 56 | 2004-03-01 | 2013-06-05 |
| Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers imatinib mesylate, bevacizumab, pharmacological study - Recurrent Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2003-10-01 | 2018-06-20 |
| Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma allovectin-7 - Stage IV Melanoma, Stage III Melanoma | Phase 2 | Completed | Vical | 78 | 1998-08-01 | 2011-07-07 |
| Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma dendritic cell-gp100-MART-1 antigen vaccine, sargramostim - Stage IV Melanoma, Stage III Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 2024-03-04 |
Melanoma (20) · Neoplasms (2) · Skin Neoplasms (2) · Recurrence (1) · Uveal Melanoma (1)
Neoplasms by Histologic Type (20) · Neoplasms by Site (20) · Neoplasms, Germ Cell and Embryonal (20) · Neoplasms, Nerve Tissue (20) · Neuroectodermal Tumors (20) · Neuroendocrine Tumors (20) · Nevi and Melanomas (20) · Skin Diseases (20) · Skin and Connective Tissue Diseases (20) · Neoplasms (18) · Skin Neoplasms (18) · Disease Attributes (1) · Eye Diseases (1) · Eye Neoplasms (1) · Pathologic Processes (1)
pembrolizumab (4) · Ipilimumab (2) · Nivolumab (2) · Sorafenib (2) · sargramostim (2) · 1-methyltryptophan (1) · Allovectin-7 (1) · Bevacizumab (1) · Biopsy (1) · Cilengitide (1) · Dacarbazine (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Imatinib Mesylate (1) · Immunohistochemistry (1) · Interleukin-2 (1)
National Cancer Institute (NCI) (7) · Assistance Publique - Hôpitaux de Paris (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · Fred Hutchinson Cancer Center (1) · Mannkind Corporation (1) · Medical University of Vienna (1) · NewLink Genetics Corporation (1) · St. Louis University (1) · UNC Lineberger Comprehensive Cancer Center (1) · Universitair Ziekenhuis Brussel (1) · University of California, Irvine (1) · University of Colorado, Denver (1) · Vical (1)
United States (14) · Austria (1) · Belgium (1) · France (1)
Kevin Kim (2) · Ahmad Tarhini (1) · Anna Pavlick (1) · Bart Neyns, MD, PhD (1) · Carrie Lee, MD (1) · Celeste Lebbe, MD, PhD (1) · Elizabeth Buchbinder, MD (1) · Jennifer Fernandez (1) · John Fruehauf, MD, PhD (1) · John M Richart, MD (1) · Kavita Dhodapkar, MD (1) · Keith Flaherty (1) · Klemens Rappersberger, Prof. Dr. (1) · Martin McCarter, MD (1)
PMID 21206909, PMID 29943192, PMID 39374099, PMID 42640721
N01CM62202 (2), K12CA076930 (1), N01CM62204 (1), N01CM62206 (1), N01CM62209 (1), P30CA033572 (1), R21CA137647 (1)